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                                   I. Introduction 
    Protein phosphorylation plays essential roles as intracellular regulatory mechanisms at 
 several different levels of signal transduction pathways from cell surface receptors to nuclear 
 proteins in eukaryotic cells. These reactions are catalyzed by a group of enzymes called 
 protein kinases, and studies on these kinases represent the major contribution to our under-
 standings on the malignant transformation of cells as well as the control of normal cell 
growth (for reviews, see Refs. 1— 8). 
    Based on the species of amino acid residues to be phosphorylated, protein kinases can 
be classified into two groups (1, 2, 5); one is protein-tyrosine kinase which phosphorylates 
tyrosine residues on substrate proteins and the other is serine/threonine kinase which phos-
phorylates serine or threonine residues or both. In contrast to serine/threonine kinases 
whose activities have been identified early and found to be distributed abundantly in various 
types of cells (2), the tyrosine kinase activity was identified rather recently in the product of 
the src gene which is a transforming gene (oncogene) of an avian retrovirus, Rous sarcoma 
virus (RSV) (10, 11, 22). This finding established a unique protein kinase with activity of 
phosphorylating the tyrosine residue which is directly involved in the neoplastic tumor 
formation. The importance of the protein-tyrosine kinase was further emphasized by the 
identification of this enzymatic activity in a variety of oncogene proteins, including fes, fgr, 
fms, ros, and yes (5, 14-21). Several of these genes were found to encode receptors for 
growth factors, and confirmed that tyrosine kinases play essential roles for the control of 
cell growth. Accumulation of the information on such genes also made it possible to clas-
sify the protein-tyrosine kinases into two groups based on their structural and functional 
features: one is nonreceptor tyrosine kinases which are localized in cytosolic fraction and 
the other is receptor tyrosine kinases which are transmembrane molecules (1, 5). 
    Structural and functional characteristics of protein-tyrosine kinases identified originally 
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          as viral oncogenes are twofold; first, primary structures of oncogenes are altered from those 
          of normal cellular counterparts from which viral genes derived, and second, the protein 
          kinase activity is found to be enhanced constitutively, otherwise regulated in response to 
          growth conditions. Structure-function relationships of oncogenes have been extensively 
          analyzed and through these studies, the regulatory mechanisms of the tyrosine kinase activi-
          ties have become elucidated. 
            The author has been interested in the signal transduction pathways through the protein-
          tyrosine kinases and engaged in the characterization of the src protein (a nonreceptor tyro-
         sine kinase) and the fibroblast growth factor (FGF) receptor (a receptor tyrosine kinase). 
          In this article, experiments which have been carried out to clarify the structure-function re-
         lationships of the two protein kinases will be described; these include i) introduction of 
         mutations into the src protein, ii) biochemical and biological characterizations of the mu-
         tated src proteins, and iii) isolation and identification of the isoforms of the FGF receptors. 
         Finally, the significance of these findings will be discussed in perspective of receptor and 
          nonreceptor tyrosine kinases. 
 H. Structure-function relationships of the src protein 
         1) The src protein 
pp60"-S`° is encoded by the transforming gene (the v-src gene) of an avian retrovirus 
         RSV, and numerous biochemical and genetical studies showed that the expression of pp60"- 
91'C is primarily responsible for both tumor formation in vivo and cellular transformation in 
          vitro caused by the infection of RSV (for reviews, see Refs. 9-12). pp60`-Sr i`s the product 
         of its cellular homolog (the c-src gene), and comparison of the predicted amino acid se- 
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                        Fig. 1 Construction of the chimeric src gene between v-src and c-
                                src653). A) shaded and open box code for v-src and c-src se-
                              quence, respectively. Transforming ability (+, positive; —, 
                              negative) is also indicated. B) Summary of the differences
                                  in the primary structures between pp60`-5rcand pp60"-src
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quences of the two molecules revealed their strong similarities in the primary structures ex-
cept for both scattered point mutations and total replacement at their carboxy-termini; the 
last 19 residues of  pp60`_src (amino acids 515 to 533) are replaced by 12 unrelated residues 
in pp60"-5" (Fig. 1B) (23). Both pp60"-6iC and pp60`-6C` are membrane-bound phosphopro-
teins that exhibit protein-tyrosine kinase activity. Despite these similar characteristics, 
pp600-src cannot transform avian and mammalian cells even when expressed to the same 
level as that of pp60"-src (24-26). This observation attracted attentions on the analysis on 
the structure-functional relationship of the src protein. 
2) Structural and functional domains of the src protein 
   The overall structure of the src protein can be viewed as a series of interactive struc-
tural and functional domains of which boundaries have been defined by the amino acid se-
quence comparison with other protein kinases and the results of biochemical and genetical 
analyses; they are a) myristylation domain, b) modulatory domain, c) kinase domain and d) 
regulatory domain (Fig. 2) (11). 
     myristic acid QVQ 
Gly-2Tyr-416 Tyr-527 
                   0.^ 11' r. ,: j COON 
            MyristylationModulatoryKinase Regulatory 
       DomainDomainDomain Domain 
              Fig. 2 Schematic diagram of the functional domains of pp60`-sr`(10) 
pp60`'" consists of 533 amino acids and the domain struc-
                    ture is predicted based on sequence comparison and inter-
                    pretation of genetic data (see text). Possible sites of serine 
                    and tyrosine phosphorylation are indicated as P . Gly-2 is a 
myristylation site. 
a) Myristylation domain 
pp60"-"c as well as pp60c-src is associated with the inner face of the plasma membrane 
through myristic acid covalently attached to Gly-2 (26-29). This association is critical in 
viral transformation; mutants of pp60"-Sr` which do not associate with membranes do not 
transform cells, notwithstanding these mutants retain wild type kinase activity (28). Sub-
stitution of amino acid residues 11-15 of pp60"-src does not alter the transforming potential 
nor the membrane association of the mutated src protein through the myristylation (29), 
suggesting that sequences required for efficient myristylation reside within the amino-ter-
minal 10 residues of pp60V-6C` of which sequence is conserved in pp60c-src as well. 
b) Modulatory domain 
   The region downstream to the myristylation domain of the src protein (amino acids 84 
to 241) has been identified to be fairly conserved among the src protein and most of other 
nonreceptor tyrosine kinases, and divided further into two subdomains based on structural 
and functional features; SH-2 (Src Homology-2) and SH-3 (Src Homology-3) (31, 32). The 
SH-2 domain encompasses about 100 amino acids immediately amino-terminal to the cata-
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lytic domain (see below), whereas the SH-3 domain encompasses about 50 amino acids 
amino-terminal to the SH-2 domain. Several lines of evidence showed the possible involve-
ment of these two domains in cellular transformation somehow (11); i) CEF infected by 
 pp60"-S`° with a deletion of amino acids 116-141 showed fusiform morphology compared to 
round refractile one by wild type pp60"-src (37), ii) Introduction of longer deletion in this re-
gion (e.g., amino acids 100-200) impaired the transforming ability of pp60"-57C although 
the kinase activity was still retained (30), and iii) amino acid substitutions at amino acids 95 
and 96 of pp60'10 conferred the transforming activity to pp60`-S" (53). These results fur-
ther suggest that the SH-2 domain is a positive regulatory domain and in contrast to the 
SH-2 domain, the SH-3 domain is a negative regulatory domain. The sequences related to 
either the SH-2 or SH-3 domain have been identified recently in several other proteins with 
or without protein kinase activity (31— 36), and this will be discussed below. 
c) Kinase domain 
   Accumulation of the DNA sequences of protein kinases made it possible to compare 
the deduced primary structures among them, and revealed the presence of highly conserved 
sequences in individual kinase including Ser/Thr kinases (5). This sequence spans in the 
region of amino acid residues 270 to 516 in the src protein. In fact, a carboxy-terminal 
30kDa proteolytic fragment containing this region was shown to exhibit tyrosine kinase 
activity in vitro confirmed that the catalytic domain of pp60 is contained within this region 
(38). The well conserved sequence for ATP binding site (GXGXXG: G, glycine; X, any 
amino acid: amino acids 274-279) is seen in this region, and is followed by a lysine residue 
(amino acid 295) 16 residues downstream which is believed to be an acceptor site of y-phos-
phate. Analysis of temperature sensitive mutants of RSV directly showed that mutations 
within the catalytic domain actually affect on kinase activity and transforming potential as 
well (39). Taken together, these results and observations mutually contributed to establish 
a concept of the "kinase domain". 
d) Regulatory region 
   The carboxy-terminal sequence of pp60C-5LC is totally replaced by an unrelated sequence 
in pp60"-src as described (23). By using chimeric molecules of pp60°-Sr` of which carboxy-
terminal region is replaced by the corresponding region of pp60"-Sr` the structural difference 
in this region solely was shown to be sufficient to convert nontransforming pp60`-sr` to a 
transforming protein (53), suggesting that this carboxy-end region plays an important role 
for the regulation of biological activity. The critical residue(s) has been identified directly 
by using a mutant molecule of which Tyr-527, major phosphorylation site of pp60°'Src in 
vivo, was substituted with Phe (40-42); the mutated pp60e-src molecules showed enhanced 
kinase activity, caused morphological transformation of CEF or mouse cells, and formed 
foci in soft agar medium. 
   Since the sequences in the carboxy-terminal regions including the residue corresponding 
to Tyr-527 of pp60`-Sr` are fairly conserved among nonreceptor tyrosine kinases, the nega-
tive regulation of the kinase activity by phosphorylation of the tyrosine residue seems to be 
common (12). 
3) pp60 as a phosphoprotein 
a) Phosphorylation sites in vivo 
13oth pp60c sr` and pp60"-src are known to be phosphorylated at multiple sites in vivo. 
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Major sites on  pp60`-Sr° are Ser-17 and Tyr-527, whereas Ser-17 and Tyr-416 on pp60"-SLO (43 
—47). Ser-17 is next to the consensus sequence for the reported recognition site of cAMP-
dependent protein kinase (A-kinase) and the phosphorylation by A-kinase has been proven 
by in vitro reaction (47). Tyr-416 is believed to be phosphorylated by an either inter- or 
intramolecular phosphotransferase activity of pp60"'src by itself (48). On the other hand, 
Tyr-527 is believed to be phosphorylated in two ways; one is by intermolecular phospho-
transfer reaction of pp60c-src and the other is exogenously by another PTK distinct from 
pp60c-sr`. Recently, a protein-tyrosine kinase which might be responsible for the latter 
reaction has been isolated from rat brain and the gene has also been molecularly cloned 
(49, 50). This enzyme, named CSK (c-src kinase), was shown to contain the SH-2 and SH-
3 domains similar to the src protein. However, the amino acid identity to the src protein is 
not more than 47%, and moreover, neither putative phosphorylation sites corresponding to 
Tyr-416 and Tyr-527 nor the site for myristylation signal was not found. 
b) Amino acid substitution and activation of pp60`-src 
   Overexpressed c-src is unable to transform CEF or mouse cells in vitro (25-27). 
pp60`-src has been shown to possess lower kinase activity than that of pp60"-sr° (51, 52), 
possibly accounting for the lack of transforming activity. With regard to this, it is feasible 
that the structural differences described above (II-1) somehow contribute to give rise to the 
difference in their kinase activities as well as their biological activities. 
   More precise experiments by using chimeric molecules between pp60c'sr` and pp60"-src 
showed that replacement of amino acids 1 to 432 (the variant NY801) or 432 to 533 of 
pp60c-sr° (the variant BB4) with the corresponding sequences of pp60v-src resulted in hybrid 
proteins with transforming activity (53). Both of these proteins showed high levels of pro-
tein kinase activity. In contrast to the latter chimeric molecule which was constructed sole-
ly by exchanging the carboxy-terminal region (II-2-d), the former chimeric molecule con-
tained scattered single amino acid substitutions between pp60"-Sr` and pp60°-src. Kato et al. 
further dissected the v-src sequence of NY801 (Fig. 1) and examined the amino acid sub-
stitution(s) that might be involved in conferring the transforming activity to pp60°-Sr` pro-
tein. As a result, they found that either the change from Thr to .Ile at position 338 
(NY901) or the replacement of Arg-95 and Thr-96 with Trp-95 and Ile-96 (NY851) was 
sufficient to convert the nontransforming pp60°-Sr° protein into a transforming protein by the 
criteria of focus formation, anchorage-independent growth and tumor formation in new 
born chicken. The resulted molecules showed in elevation of the protein kinase activity as 
well. 
c) Characterization of activated pp60`-sr` molecules 
   While the RSV variants carrying these chimeric genes (NY801, NY851, and NY901; 
Fig. 2) were transforming viruses, they gave somewhat lower titers than that of wild-type 
RSV when infected onto CEF, and the morphology of the foci produced was not so distinct 
as that of foci produced by wild type RSV. For example, many flat cells were still 
observed in NY801-infected cultures (NY851 and NY901-infected cultures as well) after 
several passages at the time when the RSV-infected cultures showed complete morphologi-
cal changes. Furthermore, pp60s encoded by these variants showed weaker kinase activi-
ties in vitro than did pp60"-src 
   Sato et al. characterized these RSV variants further to understand precisely the biolog- 
                          (575)
                                         M. SATO 
ical features unique to these variants in terms of the behaviors of the chimeric  pp60 proteins 
(54). First, protease V8 and tryptic peptide mapping analysis of 32P-labeled chimeric mole-
cules revealed the three major phosphorylation sites in each construct: Ser-17, Tyr-416 and 
Tyr-527. This was a quite contrast to normal pp60`-Sr` and even to the NY701T7 pp60, 
another activated form of pp60', which had been identified in a transforming virus from 
the cells infected by the RSV variant carrying the c-src gene instead of the v-src gene (55). 
The phosphorylation site of the NY701T7 pp60 was reported to be solely on Tyr-416 instead 
of Tyr-527. 
   On the other hand, pp60 in colonies in soft agar which composed of fully ,transformed 
cells was found to be phosphorylated exclusively at Tyr-416 and Ser-17 in contrast to pp60 
in the variant virus-infected cells. These observations strongly suggest that the difference 
in transforming ability correlates with difference in Tyr-416 and Tyr-527 phosphorylation 
and further that the Tyr-416-phosphorylated form is an activated form of the chimeric pp60 
and a limited population of pp60 is activated in the variant-infected cells. 
   Secondly, the affinity of the chimeric molecules were examined for the detergent-in-
soluble cellular matrix. pp60"-"c has been shown to be associated with a detergent-insolu-
ble cellular matrix containing the cellular cytoskeleton. pp60`-sr`, in contrast, is not tightly 
bound to the detergent-insoluble matrix (56-58). Together, the association of the c-src 
protein to the cytoskeleton is somehow related with its transforming activity. CEF infected 
with either NY801, NY851 or NY901 and cells subcultured from colonies were labeled with 
(35S)-methionine, and pp60s were extracted with non-ionic detergent buffer after exposing 
for various times. The difference of the distribution between the soluble and resistant frac-
tions after short exposure was distinct in the NY801 pp60 (as well as the NY851 and NY901 
pp60s); about 40 to 45% of the chimeric pp60s were already solubilized within 1 min after 
exposure, while only less than 20% remained in the resistant fraction after 10 min in the 
case of the virus-infected cells. On the other hand, pp60 remained in detergent-resistant 
fraction at 1 min of extraction, and still about 40% remained after up to 10 min. Accord-
ing to Hamaguchi and Hanafusa, about 90% of pp60°-"c is solubilized within the first 2 min 
of extraction, whereas more than 70% of pp60"-Sr` remains in the resistant fraction after ex-
traction for up to 10 min (56). Thus, the NY801 pp60 in which only Tyr-416 is phosphory-
lated, associates with the detergent-insoluble cytoskeleton more tightly than does pp60°Sr° 
but less tightly than does wild-type pp60"-src 
   The correlation between the phosphorylation site of the chimeric pp60 protein and the 
stability against the detergent extraction was examined further in NY801-infected cells. It 
appears that the phosphorylation of Tyr-527 was much more intense than that of Tyr-416 in 
detergent-soluble fraction and vice versa in detergent-insoluble fraction. Thus pp60 of 
which Tyr-527 was phosphorylated had less affinity for the detergent-insoluble cellular ma-
trix than did the NY801 pp60 protein phosphorylated on Tyr-416. Therefore, phosphoryla-
tion of Tyr-416 of pp60`-sr` not Tyr-527, is favored for the affinity with detergent-insoluble 
cytoskeleton, but it is not sufficient for tight association as pp60' shows. 
   In summary, the NY801 pp60 (NY851 and NY901 as well) showed a difference in the 
affinity for the detergent-insoluble cellular matrix depending on its tyrosine-phosphorylation 
site. This indicated that either the tyrosine phosphorylation site per se determines the sta-
bility of the association or the alteration of the phosphorylation-site reflects a conformation-
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 al change that may result in the different mode of association. In other words, other fac-
        tor(s) than the primary sequence seems to determine the stability of the association of pp60 
         and the cellular matrix. 
HI. SH-2 domain of pp60`-sr`; implication for the unique phosphorylation 
                         profile in the chimeric molecules 
            The results of numerous experiments support the idea that the SH-2 domain is primari-
        ly involved in the interaction with a phosphorylated tyrosine residue (33 — 35). Substitution 
        of Arg residue which is highly conserved within the SH-2 domains results in the loss of 
        proper function (59), suggesting that an ionic interaction between phosphate group and 
         basic amino acid residue may play a role in this interaction. The scheme on such mode of 
         action was mainly deduced from the works on pp60°-6ic and can be summarized as follows. 
        Tyr-527 is believed to be phosphorylated by another PTK, possibly CSK, and phosphory-
         lated Tyr-527 interacts with the SH-2 domain of pp60o-src itself, resulting in a conformation 
        that might have an inhibitory effects on its intrinsic kinase activity. When the phosphoryla-
        tion of Tyr-527 is disturbed somehow and thereby Tyr-527 is not associated to the src SH-2 
         domain, the resulting conformation is presumed to be favorable for revealing its kinase 
        activity fully, and thus induces autophosphorylation of Tyr-416 (Fig. 3). In this case, Tyr-
                                                 .% 
              e~,yS                                                                                         Plasma 
                                                                                              membrane     Y4160Z 
rO©Y.627 
                     O"~vc-srcSuppressed Nascent form of p60 form 
                              Activated form 
                        Fig. 3 Model for regulation ofthe kinase activity of pp60`-sr` by 
                               phosphorylation on tyrosine residue(7'33). Try-527 phos-
                              phorylated by CSK (c-src kinase) associates with the SH-2
                               region of the same pp60`-s" molecule, leading the molecule
                              to the suppressed form with low kinase activity. Dephos-
                            phorylation of phosphotyrosine-527 is needed for taking the 
                              activated form. Tyr-416 will be phosphorylated by auto-
                              phosphorylation in this form. Er, Sh-2 region; K, Active
                               site; Y, tyrosine residue; S, substrate. 
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416 could associate with other protein through the SH-2 domain. The chimeric pp60  mole-
cules described above are presumed to be unable to be fully phosphorylated by CSK due to 
amino acid substitutions, giving rise to a population of unphosphorylated form of pp60 pro-
teins on Tyr-527 which would be phosphorylated on Tyr-416 eventually. This could explain 
the presence of two species of pp60 in NY801 (NY851 and NY901 as well) infected CEF. 
The NY801 pp60 of which Tyr-416 is phosphorylated, which possesses a modest kinase 
activity, can associate with putative substrates in cytoskeletal matrix, but it is not so tight as 
pp60"-src due to the remaining amino acid substitutions. 
                IV. Receptor tyrosinekinasesvs. nonreceptor tyrosine kinases 
   Many of peptide hormones or growth factors mediate their pleiotropic actions by bind-
ing to and activating cell surface receptors (1, 3-6). The receptor for epidermal growth 
factor (EGF) was found to possess the protein-tyrosine kinase activity first (60), and the en-
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              Fig. 4 Organization of receptor-tyrosine kinases("). These recep-
                    tors consist of amino-terminal extracellular ligand binding 
                     domains, transmembrane domains and carboxy-terminal in-
                    tracellular tyrosine kinase domains. The extracellular do-
                    mains of receptors in subclasses I and II include cysteine-rich 
                    regions and those of receptors in subclasses III and IV in-
                    clude immunoglobulin-like repeats. Receptors in subclass II 
                    are composed of two subunits. The tyrosine kinase domains 
                    of receptors in subclasses III and IV are interrupted by an 
                    insertion of several amino acids (kinase insert: KI).
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zymatic activty was shown to be stimulated by EGF binding (61), suggesting that the kinase 
activity plays an important role in the signal transduction. This was further confirmed by a 
parallel observation that erbB, a transforming gene of avian erythroblastosis virus (AEV), 
encodes a truncated form of EGF receptor lacking the extracellular domain with a constitu-
tively elevated kinase activity (62, 63). In addition to these findings, several other growth 
factor receptors including the receptors for platelet-derived growth factor (PDGF), insulin, 
insulin-like growth factor (IGF-1), and fibroblast growth factor (FGF) were similarly found 
to have protein-tyrosine kinase activity  (64—  70). Receptor protein-tyrosine kinases were 
thus implicated as signal transducers in the response of cells to normal growth factors as 
well as in neoplastic transformation. 
   Comparison of the amino acid sequences of the EGF, PDGF, insulin, IGF-1, FGF, and 
CSF-1 receptors clarified the related structural organizations consisting of three major do-
mains distinct in their functions (4, 6). First, the ligand binding domain is encoded in the 
amino-terminal extracellular portions of the proteins. There is then a stretch of nearly 24 
hydrophobic amino acids which span the plasma membrane (the transmembrane domain). 
Finally, the tyrosine kinase catalytic domain is on the cytoplasmic side of the membrane, 
encoded in the carboxy-terminal portions of the proteins beginning almost 50 amino acids 
from the transmembrane region. 
   More precisely, however, on the basis of sequence similarities and distinct structural 
characteristics, it is possible to classify these receptors into 4 subclasses (Fig. 4) (6). Char-
acteristic structural features of each subclasses are the following; I) two cysteine-rich repeat 
sequences in the extracellular domain of monomeric receptors, II) disulfide-linked heter-
otetrameric structures with similar cysteine-rich sequences, III) five immunoglobulin (Ig)-
like repeats, and IV) three Ig-like repeats, respectively. The tyrosine kinase domain of the 
latter two is interrupted by hydrophilic insertion sequences of varying length (called KI). 
                         V. FGF-receptor family and isoforms 
1) Structural features of FGF receptor 
   Among the receptor tyrosine kinases, the FGF receptor (FGF-R) is unique in that 
three repeats of an Ig-like motif constitute the extracellular region (6). The details of this 
primary structure was revealed first by DNA sequence analysis of a cDNA clone encoding 
chicken basic FGF receptor (70). This Ig-like motif has the following structural features 
(13): 1) the presence of two characteristic cysteine residues, 2) the presence of a consensus 
tryptophan residue 11 or 12 amino acids from and on the carboxy-terminal side of the first 
cysteine residue, and finally 3) the presence of the consensus sequence DXGXYXC (D, 
Asp; G, Gly; Y, Tyr; C, Cys; X, any amino acid) on the amino-terminal side of the second 
cysteine residue. 
2) Chicken FGF receptor and isoforms 
   By screening chicken embryo fibroblast cDNA expression library with anti-phosphoty-
rosine antibodies, Sato et al. isolated several cDNA clones encoding basic FGF-R related 
receptor molecules and two of them were named bek and brk, respectively (73). Of the 
two genes, the bek gene was expected to encode 824 amino acids carrying the structural 
characteristics including the three Ig-like repeats. By using the similar approach, cDNA 
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clones containing three FGF-R related genes, Cekl, 2 and 3, have been cloned inde-
pendently by Pasquale (71, 72). The overall primary structure of bek was found to be 
almost identical to that of Cek3. However, despite this similarity, a significant structural 
difference was detected between the two genes; 48 amino acids between residue 316 and 
363 of the Cek3 protein are replaced by 49 amino acids in the bek gene (Fig. 5). This vari-
able region, referred to AS (alternative sequence) hereafter, is in the last of the three Ig-
like repeats and all the characteristics to the repeat were shown to be completely conserved. 
 Ig-like 
                               structure 
N 
                                            Transmembrane Kmase                 AS 
DomainDomain 
              Fig. 5 Predicted primarystructure of the FGF receptor is schemati-
                     cally shown.(73) AS: structural variation betweenbek and 
                      Cek3. 
3) Exon-intron structure 
   Structural analysis of the genomic counterpart of AS gave direct evidence that ASs for 
bek and Cek3 (Bek-AS and Cek3-AS) are located closely on the chicken genome. Structur-
al features in this region are as follows. First, two units of sequences exactly corresponding 
to bek-AS and Cek3-AS respectively were found to be localized 1.3 kb apart each other, 
and bek-specific and Cek3-specific sequences were shown to be separated from common up-
stream and downstream exons at a distance of 0.7 kb and 2.3 kb, respectively. Second, 
considering each unit is surrounded by the consensus sequence for splice donor and accep-
tor sites, two units seem to be functional exons. Finally, besides these two putative inter-
nal exons, no significant sequence for another potential AS was found in this region (data 
not shown). Taken together, bek and Cek3 specific genomic sequences could function as 
internal exons, and bek mRNA and Cek3 mRNA could be produced by alternative splicing. 
   The structural alteration identical to the chicken genes has also been detected in the 
human-bek gene; they have been named human-bek and K-sam. Both bek mRNA and K-
sam mRNA,were reported to be derived from the same premessenger (76). Sequencing of 
the genomic region for human-bek gene revealed the presence of two internal exons which 
are specific to K-sam (upstream) and bek (downstream), respectively. Overall organization 
of internal and common exons seems to be well conserved between human and chicken, 
although sizes of putative introns are not identical. 
4) Expression of bek- or Cek3-specific sequence in chicken tissues 
   The expression of the chicken-bek mRNA was examined in several tissues with a probe 
common to both Cek3 and bek and found to be expressed predominantly in lung and brain 
(73). A major transcript of 4.0 kb was found to be expressed to the similar level in these 
tissues. A bek-specific probe which was derived from the bek-AS hybridized exclusively 
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with 4.0 kb mRNA from lung, whereas Cek3-specific probe, Cek3-AS, hybridized predomi-
nantly with brain RNA and, to less extent, with lung RNA, strongly suggesting that the ex-
pression of bek and Cek3 mRNAs are regulated in a manner of tissue-specific. 
   The significance of this tissue specificity was examined more precisely by in situ hybrid-
ization histochemistry in brain and lung using digoxigenin-labeled RNA probes. Both bek 
and Cek3 probes detected the homogeneous expression in lung, whereas in brain, Cek3 
probe detected the expression in corpora medulla of cerebellum as well as in cerebrum. 
Any significant signal was hardly detected with bek probe in consistent with the results of 
northern blot analysis. 
5) Physiological significance of the existence of isoforms 
   In addition to the bek-isoforms described above, several isoforms have been identified 
in FGF-receptor family. Structural alterations generating those isoforms can be mapped at 
five sites within the receptor molecule (Table 1); 1) the first of the three Ig-like repeats is 
missing or deleted in several genes related to  flg and bek (69, 70, 75 — 84), 2) two amino 
acids insertion or deletion in the two regions was identified in fig and bek (76, 78, 80), 3) 
                Table 1. FGF receptor family and isoforms (Refs.: see text). 
          FGF-R Genes in Structural features of isoforms Ligand 
         subfamily subfamily 
        1flg 3 Ig-like repeats typeaFGF 
                 Cekl 2 Ig-like repeatstypebFGF 
                  secreted typeKFGF
                                2 aminoacidsinsertion/deletion 
                              type 
                                kinasedomaindeletion type 
        2bek 3 Ig-like repeats typeaFGF 
                 K-sam 2 Ig-like repeatstypebFGF 
                     Cek3 2 amino acids insertion/deletion KGF 
     KGF-R type  
       3 Cek2,brk 3 Ig-like repeats type  
          4 FGF-R 3 3 Ig-like repeats typeaFGF, bFGF  
        5 FGF-R 4 3 Ig-like repeats typeaFGF  
deletion in the carboxy-terminal region of kinase domain has been reported in human fig 
(80), 4) a stretch of amino acid residues has been replaced with distantly related sequence 
in bek as described in this article (72, 73, 79, 82), and finally 5) truncated forms consisting 
of a part of ,extracellular domain and thus could be secreted from the cell have been identi-
fied in flg and bek (78, 84). Several lines of evidence indicate that alternative splicing is 
primarily involved in generating such diverse FGF receptor isoforms. 
   The biological significance of the existence of diverse isoforms and the physiological 
role of each receptor molecule are mostly unclear. With regard to this, two isoforms of fig 
consisting of two and three Ig-like motifs respectively have been reported to show no signif-
icant difference in the binding activity of either acidic FGF or basic FGF, indicating that at 
least the amino-terminal first Ig-like motif seems to have no significant role for the binding 
of ligand of fig (84). At present, the following possibilities can be listed in considering the 
significance of isoforms; 1) structural variations may be involved in tissue specific expression 
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        as described above, 2) structural differences are directly involved in the ligand specificity, 3) 
         the structural change close to transmembrane domain may affect the localization or dimer-
         ization in plasma membrane, 4) some of the isoforms are inactive form and the formation of 
        heterodimer between active and inactive form is responsible for the inhibitory effect, 5) the 
        truncated form could be a noncompetitive inhibitor for the ligand binding, and finally 6) the 
         structural alteration in the kinase domain could affect on the tyrosine kinase activity as well 
         as the substrate specificity, modulating the signal transduction pathway in the cell. 
            Recently, it appears that proteoglycans such as heparin or heparan sulfate play impor-
        tant roles for growth factor activities by binding to both extracellular proteins and growth 
         factors, suggesting that the role of structural variations identified within extracellular  do-
        main could affect the interaction with such modulators (86-89). 
                                            VI. Conclusions 
            Both the receptor and nonreceptor protein-tyrosine kinases can be viewed as transduc-
        ers of information within the cell. They respond to activating stimuli by increasing their 
         catalytic activities and transfer information to target molecules by phosphorylation, raising 
        two important questions; how their activities are regulated and which proteins are their sub-
           strates. 
           The enhancement of catalytic activity of the receptor is initiated by the binding of the 
         genuine growth factor to its extracellular domain. This induces dimerization (tetrameriza-
         tion in case of subgroup II) of homologous monomer, and the resulting conformational 
        change is believed to enhance its intrinsic kinase activity somehow, leading to the autophos-
        phorylation on tyrosine residue(s) within the kinase domain (6, 90, 91). The phosphory-
         lated receptor molecules are now able to associate with other proteins carrying the SH-2 do-
         main and phosphorylate them to transduce signals. Among proteins to be recognized by 
         receptors, several proteins functioning in the metabolism of second messengers are known 
        to be regulated in such a manner; for example, such as phospholipase C-y (PLC-7), 
        GTPase activating protein (GAP) and phosphatidylinositol 3-phosphate kinase (PI-3 kinase) 
        (6, 7, 92-97). 
            In contrast, nonreceptor tyrosine kinases are not exposed to the external environment 
        of the cell, and are regulated either by other cytosolic protein kinases or by linking nonco-
        valently to receptors with or without protein kinase activity. Indeed, several nonreceptor 
        tyrosine kinases (fyn, lyn, and lck), which belong to src family, are reported to interact with 
        cell surface receptor proteins, such as CD4, CD8, T-cell receptor and sIgM, which have no 
        intrinsic kinase activity (98-101). In this case, the nonreceptor kinases would be func-
        tionally equivalent to the catalytic domains of the receptor kinases and thus the activation 
         mechanisms seem very similar between two types of PTKs. Furthermore, the association 
        of several src family proteins with PDGF receptor has also been reported (102). 
           An important subject which was practically untouched in this review, mainly due to 
        limited space, is presenting a picture of the physiologically relevant substrates for protein-
        tyrosine kinases, especially for the nonreceptor tyrosine kinases. Transformation by the 
        oncogenes encoding protein-tyrosine kinases, as well as physiological stimulation of receptor 
        tyrosine kinases results in a substantial increase in the level of phosphotyrosine in cells. A 
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large number of proteins to be specifically phosphorylated on tyrosine residues in trans-
formed or growth factor stimulated cells have been  reported; previously identified proteins 
include major cytoskeletal proteins which are related to lipocortins, vinculin and the gly-
colytic enzymes enolase, phoshoglycerate mutase, and lactate dehydrogenase (103-105). 
However, none of these represent molecules that have been clearly implicated in the induc-
tion of a mitogenic response. In addition, these putative substrates have also been re-
ported to be phosphorylated in nontransformed cells expressing mutant src proteins which 
are transformation defective in spite of being active kinases (106). Recently, by using 
different approaches with anti-phosphotyrosine antibodies and more refined cell fractiona-
tion procedures, a set of proteins containing tyrosine residues of which phosphorylation 
were fairly correlated with other transformation parameters have been identified. Precise 
analyses on these proteins should give us useful information to understand the signal trans-
duction pathways involved in normal cells as well as transformed cells. 
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